What question did this study set out to answer?

This research explores how allogeneic CAR T cells can mitigate challenges in glioblastoma treatment.

March 3, 2021Open Access

Allogeneic CAR T Cells: An Alternative to Overcome Challenges of CAR T Cell Therapy in Glioblastoma

Key Points

This research explores how allogeneic CAR T cells can mitigate challenges in glioblastoma treatment.
Discusses CRISPR/Cas9 technology in relation to CAR T cell therapy challenges.
Explores approaches for altering the tumor microenvironment using allogeneic CAR T cells.
Allogeneic CAR T cell therapies could reduce graft-vs-host disease and host allorejection.
Next generation therapies for glioblastoma may benefit from multivalent approaches.

Abstract

CRISPR/Cas9, might allow overcoming the two main limitations of allogeneic CAR T cells product, i.e., graft-vs.-host disease and host allorejection. Here, we will discuss how allogeneic CAR T cells could allow for multivalent approaches and alteration of the tumor microenvironment, potentially allowing the development of next generation therapies for the treatment of patients with GBM.

Read Full Paperexternally

KI fragen

Bookmark

View Full Paper